Moderna posts surprise profit

Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna shares surge after vaccine maker posts unexpected third-quarter profit
Investing.com - Moderna (NASDAQ:MRNA) has reported a surprise net income in the third quarter and announced changes at its leadership team, as the drugmaker looks to address issues stemming from fading sales of its COVID-19 vaccine since
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna sales get lift from early nod for newest COVID shot
The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement Thursday, helping drive product sales up 3.6 percent.
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine Sales
Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales. Moderna’s earnings per share and revenue surpassed Wall Street expectations, with earnings reaching a surprising profit and revenue exceeding projected figures.
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...
BioPharma Dive3d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...
Bizcommunity3d
Leadership shakeup at Moderna ahead of major vaccine rollouts
Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...
Cautious Outlook for Moderna Amid Market Challenges and Shrinking Growth Prospects
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...